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Background: The biological phenomenon of cell fusion has been linked to several characteristics of tumour
progression, including an enhanced metastatogenic capacity and an enhanced drug resistance of hybrid cells. We
demonstrated recently that M13SV1-EGFP-Neo breast epithelial cells exhibiting stem cell characteristics
spontaneously fused with MDA-MB-435-Hyg breast cancer cells, thereby giving rise to stable M13MDA435 hybrid
cells, which are characterised by a unique gene expression profile and migratory behaviour. Here we investigated
the involvement of the PLC-b/g1, PI3K/AKT and RAS-RAF-ERK signal transduction cascades in the EGF and SDF-1a
induced migration of two M13MDA435 hybrid cell clones in comparison to their parental cells.
Results: Analysis of the migratory behaviour by using the three-dimensional collagen matrix migration assay
showed that M13SV1-EGFP-Neo cells as well as M13MDA435 hybrid cells, but not the breast cancer cell line,
responded to EGF stimulation with an increased locomotory activity. By contrast, SDF-1a solely stimulated the
migration of M13SV1-EGFP-Neo cells, whereas the migratory activity of the other cell lines was blocked. Analysis of
signal transduction cascades revealed a putative differential RAF-AKT crosstalk in M13MDA435-1 and -3 hybrid cell
clones. The PI3K inhibitor Ly294002 effectively blocked the EGF induced migration of M13MDA435-3 hybrid cells,
whereas the EGF induced locomotion of M13MDA435-1 hybrid cells was markedly increased. Analysis of RAF-1
S259 phosphorylation, being a major mediator of the negative regulation of RAF-1 by AKT, showed decreased
pRAF-1 S259 levels in LY294002 treated M13MDA435-1 hybrid cells. By contrast, pRAF-1 S259 levels remained
unaltered in the other cell lines. Inhibition of PI3K/AKT signalling by Ly294002 relieves the AKT mediated
phosphorylation of RAF-1, thereby restoring MAPK signalling.
Conclusions: Here we show that hybrid cells could evolve exhibiting a differential active RAF-AKT crosstalk.
Because PI3K/AKT signalling has been chosen as a target for anti-cancer therapies our data might point to a
possible severe side effect of AKT targeted cancer therapies. Inhibition of PI3K/AKT signalling in RAF-AKT crosstalk
positive cancer (hybrid) cells could result in a progression of these cells. Thus, not only the receptor (activation)
status, but also the activation of signal transduction molecules should be analysed thoroughly prior to therapy.
Background
The biological phenomenon of cell fusion plays a funda-
mental role in a plethora of physiological events as well
as pathophysiological events (an overview is given in
[1]). In cancer, the fusion between tumour cells and
tumour cells as well as tumour cells and normal cells,
has been linked to several characteristics of tumour pro-
gression, including an enhanced metastatogenic capacity
and an enhanced drug resistance [2-8]. Additionally, cell
fusion has also been suggested as one process how can-
cer stem cells could originate [9-12].
The hypothesis that cell fusion might play a crucial
role in tumour progression was postulated by the Ger-
man Physician Otto Aichel about 100 years ago [4]. In
his outstanding work, Aichel proposed that fusion
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tumour cells exhibiting leukocyte characteristics, such as
the ability to migrate [4]. The subject “cell fusion in
cancer” is still controversially debated [10,11,13,14] and
till now considerably less is known how the multi-step
process of cell fusion [15] between tumour cells and
other cells is regulated, which also belongs to the mole-
cules being involved in this process. Most of the identi-
fied fusion-mediating molecules, e.g., CD47 [16], CD44
[16], CD200 [17], and syncytin-1 [18-20], are expressed
on cell types, such as macrophages, knowing to undergo
cell fusion during physiological processes. Recent data
indicate that fusion events were increased about 10 to
100-fold in liver, brain and intestine in chronic inflam-
matory conditions [21-23] suggesting that inflammation
might be a strong trigger for cell fusion. Since tumour
tissue resembles chronically inflamed tissue [24-26] the
tumour microenvironment itself might thus provide a
surrounding area that trigger the fusion of tumour cells
with other cells.
Recent data of the past years provided evidence that
cell fusion is a common event in cancer [27-29]. By
using a parabiosis model, a GFP mouse was surgically
joined with an APC
Min/+ mouse, Powell et al. demon-
strated recently that cell fusion in tumour tissue
between cancer cells and macrophages and B- and T-
Lymphocytes occurred in vivo [28]. Analysis of the gene
expression profile of hybrid cells showed that these cells
retain a transcriptome identity characteristic of both
parental derivatives, while also expressing a unique sub-
set of transcripts, which may have important conse-
quences for tumorigenesis and metastogenesis [28]. A
unique gene expression pattern was further described
for hybrid cells derived from weakly malignant Cloud-
man S91 melanoma cells and macrophages [30,31],
human breast epithelial cells exhibiting stem cell charac-
teristics and breast cancer cells [7], and murine 67NR
mammary carcinoma cells and mouse bone marrow-
derived cells (BMDCs) [8]. Rizvi and colleagues provided
evidence that murine BMDCs restore murine intestinal
tissue in a long term repopulation fashion suggesting
that BMDCs have fused with intestinal stem and/or pro-
genitor cells [29]. These data let assume that macro-
phages and/or BMDCs will preferentially fuse with
cancer stem/progenitor cells in order to ensure tumour
tissue homeostasis.
Recently, we demonstrated that human mammary
epithelial cells exhibiting stem cell characteristics spon-
taneous fuse with human breast cancer cells, thereby
giving rise to stable hybrids [32]. These cells were char-
acterised by a nearly doubled chromosomal number and
an increased proliferation rate [10] as well as a unique
gene expression profile concomitant with an altered
migratory behaviour [7]. In the present work we
analysed the role of three major cell migration related
signal transduction cascades - PLC-g1, PI3K/AKT, RAS-
RAF-MAPK - in two hybrid cell lines and their parental
cells. Since these hybrid cell lines were also positive for
the stromal cell-derived factor-1a (SDF-1a) receptor
CXCR4 we additionally investigated both the effect of
EGF and SDF-1a. Our data show that each hybrid cell
line exhibited a unique signal transduction cascade
kinetics pattern including a differential activity of the
RAF-AKT crosstalk.
Results
Flow cytometry analysis of EGFR family members and
CXCR4
In the present study we investigated the migratory activ-
ity of M13MDA435-1 and -3 hybrid clones and their
parental cells (M13SV1-EGFP-Neo breast epithelial cells
and MDA-MB-435-Hyg breast cancer cells) in response
to EGF and SDF-1a. Both hybrid clones derived from
spontaneous fusion events between M13SV1-EGFP-Neo
cells and MDA-MB-435-Hyg cells and were isolated by
a dual antibiotic selection procedure [7]. Parental cells
were co-cultured for 24 h prior to addition of antibiotics
[7]. The origin of hybrid cells by cell fusion and not
horizontal gene transfer was proven by short tandem
repeat (STR) analysis, whereby specific sequences on dif-
ferent chromosomes were analyzed. STR analysis
revealed an overlap of parental alleles in hybrid clone
M13MDA435-3 (Figure 1A; Table 1), which is in accor-
dance to M13MDA435-1 hybrids [7]. EGFR, HER2,
HER3 and membrane bound CXCR4 expression levels
of M13SV1-EGFP-Neo breast epithelial cells, MDA-MB-
435-Hyg breast cancer cells and M13MDA435-1 hybrid
cells were comparable to previously published data [7].
Compared to hybrid clone M13MDA435-1 MDA-MB-
435-3 hybrid cells showed weaker expression levels of
EGFR, HER2 and HER3, but comparable levels of mem-
brane bound CXCR4 (Figure 1B). Because CXCR4 could
also be stored in intracellular vesicles [33], we addition-
ally performed flow cytometry studies to look for intra-
cellular localized CXCR4 in hybrid cells and parental
cells. Data are summarized in Figure 1B and clearly
show that all cells harbour similar levels of intracellular
CXCR4, which is in accordance to PCR data (data not
shown).
Migration analysis of breast epithelial cells/breast cancer
cell hybrids
Due to expression of EGFR family members and CXCR4
the migratory activity of M13MDA435 hybrid cells in
dependence of EGF and SDF-1a stimulation was investi-
gated by using the three-dimensional collagen matrix
migration assay [7,34-36]. M13SV1-EGFP-Neo breast
epithelial cells exhibiting stem cell properties responded
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activity, which is in accordance to previously published
data [7] (Figure 2A). Likewise, MDA-MB-435-Hyg
breast cancer cells did not respond to EGF stimulation
(Figure 2D). Both hybrid cell lines showed an increased
migratory activity upon EGF stimulation (Figure 2B, C).
Figure 1 STR-analysis and flow cytometry. A) Shown are representative data for the D16S402 PCR. Breast epithelial cell specific alleles are
marked by a black dashed line, whereas a grey dashed line marks breast cancer cell specific alleles. Black filled histograms represent the
predominant detected alleles. An overlay of parental alleles is clearly detectable in hybrid cells. B) Flow cytometry analysis of EGFR, HER2, HER3,
and CXCR4 (membrane bound and intracellular). Shown are representative data of one of at least three independent measurements. White
histogram: isotype control, grey histogram: specific antibody.
Table 1 Genotypic analysis of M13SV1-EGFP-Neo/MDA-MB-435-Hyg hybrid cells
Primer M13SV1-EGFP-Neo M13MDA-435-1 M13MDA-435-3 MDA-MB-435-Hyg









94 94 94 94
143 143 143
149 149 149 149
173 173 173
175 175 175
CASSR1 114 114 114 114
132
a These primer pairs were used for the multiplex PCR
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induced locomotory activity of M13MDA435-1 cells was
slightly higher (Figure 2B, C), which might be attributed
to the cells higher EGFR, HER2, and HER3 expression
levels (Figure 1B).
M13SV1-EGFP-Neo breast epithelial cells exhibiting
stem cell characteristics responded to SDF-1a stimula-
tion with a slightly, but not significantly increased loco-
motory activity (Figure 2A). Interestingly, the migratory
activity of MDA-MB-435-Hyg breast cancer cells was
decreased by SDF-1a (Figure 2D). Because cells possess
marked levels of intracellular CXCR4, but not mem-
brane bound CXCR4, we assume that upon SDF-1a sti-
mulation CXCR4 from intracellular compartments is
transported to the surface. In accordance to MDA-MB-
435-Hyg breast cancer cells the migratory activity of
both hybrid cell lines was effectively blocked by SDF-1a
(Figure 2B, C).
Calcium measurements
In order to investigate whether the differential suscept-
ibility of all analysed cells towards EGF and SDF-1a was
attributed to a differential engagement of signal trans-
duction pathways we first conducted flow cytometry-
based calcium measurements to determine whether
PLC-b/g1 signalling was activated upon EGF and SDF-
1a stimulation. Data are summarized in Figure 3 and
clearly show that only EGF stimulation of M13SV1-
EGFP-Neo cells resulted in increased intracellular cal-
cium concentrations.
Figure 2 Cell migration data. The migratory activity was analyzed using the 3D collagen matrix migration assay combined with time-lapse
video-microscopy. For a better comparison of the EGF and SDF-1a specific, values of each cell type were calculated in relation to untreated
control values, which were set to 100%. Cells were stimulated with 100 ng/ml EGF; 1 μg/ml SDF-1a, 500 nM L294002, and 500 nM PD98059. A)
M13SV1-EGFP-Neo breast epithelial cells, B) M13MDA435-1 hybrid cells, C) M13MDA435-3 hybrid cells, D) MDA-MB-435-Hyg breast cancer cells.
Statistical significance was calculated using Student’s t-test: n.s. = not significant; * = p < 0.05; ** = p < 0.01; *** = p = 0.001.
Özel et al. Cell Communication and Signaling 2012, 10:10
http://www.biosignaling.com/content/10/1/10
Page 4 of 12M13MDA435 hybrids exhibit a differential PI3K/AKT and
MAPK
p42/44 signalling
We next analysed the function of PI3K/AKT and
MAPK
p42/44 signalling by using the well characterised
pharmacological inhibitors Ly294002 (PI3K inhibitor)
and PD98059 (MAPK
p42/44 inhibitor). Ly294002 treat-
ment inhibited both the EGF and SDF-1a induced
migration of M13SV1-EGFP-Neo breast epithelial cells
exhibiting stem cells characteristics (Figure 2A). In con-
trast to this, PD98059 solely blocked the spontaneous
migration of M13SV1-EGFP-Neo cells, but had no inhi-
bitory effect on the EGF and SDF-1a induced migration
(Figure 2A). Stimulation of M13SV1-EGFP-Neo cells
with EGF resulted in increased pAKT and pMAPK
p42/44
levels, which were markedly blocked by Ly294002 and
PD98059 treatment (Figure 4A). Similar data were
obtained for SDF-1a, whereby the increase in AKT and
MAPK
p42/44 phosphorylation was rather moderate as
compared to EGF stimulated cells (Figure 4A). Likewise,
SDF-1a mediated phosphorylation of AKT and
MAPK
p42/44 was effectively blocked by both Ly294002
and PD98059 treatment (Figure 4A).
Treatment of MDA-MB-435-Hyg breast cancer cells
with Ly294002 and PD98059 showed that only PD98059
significantly impaired the cells’ spontaneous migration
(Figure 2D). Ly294002 blocked the inhibitory effect of
SDF-1a on MDA-MB-435-Hyg cells, whereby this effect
was not significant (Figure 2D). Western Blot analysis of
EGF and stimulated MDA-MB-435-Hyg cells revealed
increased pAKT levels upon EGF stimulation, which
were effectively blocked by Ly294002 (Figure 4D). By
contrast, no MAPK
p42/44 phosphorylation was detected
in EGF treated MDA-MB-435-Hyg cells (Figure 4D). Sti-
mulation of MDA-MB-435-Hyg breast cancer cells with
SDF-1a did neither result in AKT nor in MAPK
p42/44
phosphorylation (Figure 4D).
Analysis of M13MDA435-1 and M13MDA435-3
hybrid cells resulted in totally different outcomes. The
spontaneous as well as the EGF induced migration of
M13MDA435-3 hybrid cells were markedly impaired by
both Ly294002 and PD98059 (Figure 2C). Likewise, the
migratory activity of MDA-MB-435-Hyg breast cancer
cells co-treated with either SDF-1a and Ly294002 or
SDF-1a and PD98059 was comparable to the locomo-
tory behaviour of cells treated with the appropriate inhi-
bitor alone (Figure 2C). These data indicate that both
inhibitors rather blocked the spontaneous migration of
M13MDA435-3 hybrid cells than the factor-specific
mediated migratory activities. Otherwise, one would
have expected a more profound inhibitory effect of
Ly294002 on the EGF induced migration. Western Blot
data of M13MDA435-3 hybrid cells were comparable to
M13SV1-EGFP-Neo cells. Both EGF and SDF-1a treat-
ment resulted in increased pAKT and pMAPK
p42/44
levels, which were blocked by Ly294002 and PD98059
(Figure 4C).
Figure 3 Calcium measurements. The diagram shows the mean calcium influx in EGF and SDF-1a treated cells. An increase in cytosolic
calcium concentrations was only observed in EGF stimulated M13Sv1-EGFP-Neo cells. Shown are the mean of at least three independent
experiments.
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the PI3K inhibitor Ly294002 potently induced the spon-
taneous migration as well as the EGF induced migration
of M13MDA435-1 hybrid cells (Figure 2B). Moreover,
Ly294002 effectively reverted the inhibitory effect of
SDF-1a on the migration of this hybrid clone (Figure
2B) clearly indicating the stimulatory effect of this inhi-
bitor on the migratory activity of M13MDA435-1 hybrid
cells. PD98059 inhibited both the spontaneous and the
EGF induced migration (Figure 2B), which is in accor-
dance to M13MDA435-3 hybrid cells, but opposite to
M13SV1-EGFP-Neo breast epithelial cells (Figure 2A,C).
The locomotory activity of PD98059 treated
M13MDA435-1 hybrid cells was comparable to the
migratory activity of solely SDF-1a treated as well as
SDF-1a and PD98059 co-treated cells (Figure 2B). In
accordance to all other analysed cells EGF and SDF-1a
stimulation resulted in increased pAKT levels in
M13MDA435-1 hybrid cells, which were effectively
blocked by Ly294002 (Figure 4B). Likewise, both EGF
and SDF-1a stimulation resulted in increased
pMAPK
p42/44 levels in M13MDA435-1 hybrid cells,
which were impaired by PD98059 (Figure 4B). Interest-
ingly, in contrast to M13SV1-EGFP-Neo breast epithelial
cells and M13MDA435-3 hybrids phosphorylated
MAPK
p42/44 levels were also clearly detectable in
Ly294002 treated M13MDA435-1 hybrid cells (Figure
4B), which might be an explanation for the stimulatory
effect of this inhibitor on the migratory activity of these
cells.
Do M13MDA435-1 hybrid cells possess an altered RAF-
AKT crosstalk?
The differential effect of the PI3K inhibitor Ly294002 on
the EGF-induced migratory activity of M13DA435-1 and
M13MDA435-3 hybrid cells might be attributed to a
differential active RAF-AKT crosstalk [37,38]. AKT
mediated phosphorylation of RAF-1 at position S259 is
consistent with RAF-1 inactivation [38]. Thus Western
Blot studies were conducted to determine pRAF-1 S259
levels in cells. In M13SV1-EGFP-Neo breast epithelial
cells similar amounts of pRAF-1 S259 were detected
irrespective of applied conditions (Figure 4A), which is
opposite to MDA-MB-435-Hyg breast cancer cells.
H e r e ,n oo rs o l e l yv e r yf a i n tp R A F - 1S 2 5 9l e v e l sw e r e
detected (Figure 4D). Analysis of M13MDA435-1 and
M13MDA435-3 hybrid cells revealed different pRAF-1
S259 levels. In accordance to M13SV1-EGFP-Neo cells,
similar amounts of pRAF-1 S259 were detected in
M13MDA435-3 hybrid cells irrespective of the applied
Figure 4 Western Blot analysis of PI3K/AKT and RAS-RAF-MAPK signalling. The effect of EGF and SDF-1a on induction of PI3K/AKT and
RAS-RAF-MAPK signalling was analysed by Western Blot. Cells were stimulated for 5 minutes with 100 ng/ml EGF and 1 μg/ml SDF-1a. In case
of inhibitor treatment cells were preincubated for 30 minutes with 500 nM Ly294002 and 500 nM PD98059. The downstream effect of EGF and
SDF-1a stimulation on the AKT and MAP-kinase pathways was determined by phosphorylation of AKT and MAPK
p42/44. To investigate for the
putative RAF-AKT crosstalk RAF-1 expression and RAF-1 phosphorylation at position S259 was determined. The arrow marks pRAF-1 S259. elf4E
served as loading control. Shown are representative Western-Blot data of three independent experiments. A) M13SV1-EGFP-Neo breast epithelial
cells, B) M13MDA435-1 hybrid cells, C) M13MDA435-3 hybrid cells, D) MDA-MB-435-Hyg breast cancer cells. Bands were densitometric analysed
by using the ImageJ software http://rsbweb.nih.gov/ij/. Relative intensities of protein and phosphoprotein expression were calculated in relation
to elf4E and controls, which were set to 100%.
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S259 levels were detected in M13MDA435-1 hybrid
cells treated with Ly294002 alone or in combination
with EGF or SDF-1a (Figure 4B). These data likely sup-
port the putative RAF-AKT crosstalk in M13MDA435-1
hybrid cells. Inhibition of AKT signalling by Ly294002
impairs AKT mediated phosphorylation of RAF-1 at
position S259, thereby activating RAF-MAPK signalling.
Interestingly, we noticed slightly decreased pRAF-1
S259 levels in PD98059 treated hybrid cell lines (Figure
4). This effect was reproducible and might be attributed
to an MAPKp42/44 RAF-1 negative feedback loop
[39,40]. Due to inhibition of MAPK
p42/44 signalling by
PD98059 this negative feedback is abrogated thus pre-
venting RAF-1 S259 phosphorylation.
Discussion
In the present study we investigated the migratory activ-
ity of the two hybrid cell lines M13MDA435-1 and
M13MDA435-3 in dependence of EGF and SDF-1a sti-
mulation in comparison to M13SV1-EGFP-Neo breast
epithelial cells exhibiting stem cell characteristics and
HS578T-Hyg breast cancer cells. Our data show that
each hybrid clone exhibited a unique EGF and SDF-1a
mediated migratory activity, which was most likely
attributed to a unique signal transduction cascade
kinetics pattern in each hybrid cell clone.
Cell migration is a complex process and is directed by
the interplay of several signal transduction pathways
initiated by various ligands such as growth factors, che-
mokines and extracellular matrix components that acti-
vate growth factor receptors, chemokine receptors and
integrins [41,42]. The involvement of different pro-
migratory pathways initiated by different inducers is
nicely seen in M13SV1-EGFP-Neo breast epithelial cells
exhibiting stem cell properties. EGF treatment resulted
in a markedly induced migratory activity of the cells. In
accordance to M13MDA435-3 hybrid cells the PI3K
inhibitor Ly294002 impaired both the spontaneous and
EGF induced migration of M13SV1-EGFP-Neo cells.
However, the inhibitory effect of Ly294002 on the spon-
taneous migration of the cells was rather moderate
(about 25%), whereas the inhibitory effect of Ly294002
on the EGF induced migration of M13SV1-EGFP-Neo
cells was much higher (about 90%). This indicates that
inhibition of PI3K/AKT signalling impairs both the
spontaneous and the EGF induced migration.
Since only M13SV1-EGFP-Neo breast epithelial cells
showed an EGF-dependent calcium influx and EGFR/
HER2/PLC-g1 signalling has been suggested as a key
regulatory step in cell migration [34,43] we conclude
that the markedly increased migratory activity of the
cells in response to EGF was attributed to the induction
of this signal transduction cascade mediated by EGFR/
HER2 heterodimer signalling. Moreover, data of Falasca
and colleagues provided evidence that PLC-g1 signalling
does also depend on PI3K activity [44]. PI3K generates
phosphatidylinositol-3,4,5-triphosphate to which PLC-g1
binds with its pleckstrin homology domain [44]. By
doing so PLC-g1 translocates to the plasma membrane
and is subsequently activated by tyrosine phosphoryla-
tion [44]. PI3K is highly activated by HER2/HER3 sig-
nalling [45,46]. In the context of breast cancer HER2/
HER3 heterodimer signalling has been referred to func-
tion as an oncogenic unit [45]. Thus inhibition of PI3K
activity by Ly294002 also impairs PLC-g1s i g n a l l i n g ,
w h i c hm i g h tb eas u i t a b l ee x p lanation for the effective
inhibition of Ly294002 on the EGF induced migration of
M13SV1-EGFP-Neo cells initiated by the interplay of
EGFR/HER2/PLC-g1 and HER2/HER3/PI3K signalling.
Similar findings were recently demonstrated by Balz et
al. demonstrating that the EGF induced calcium influx
concomitant with the migratory activity was markedly
decreased in EGFR/HER2/HER3 positive MDA-HER2
breast cancer cells treated with the PI3K inhibitor wort-
mannin [47].
This assumption is further substantiated by PD98059
data. MAPK signalling does not interfere with PLC-g1
signalling and because of that inhibition of MAPK sig-
nalling did not result in a decreased EGF-induced
migration of M13SV1-EGFP-Neo cells. Moreover, these
data further show the differential roles of signal trans-
duction cascades in regulating cell migration. Even
though MAPK signalling is involved in the spontaneous
migration of M13SV1-EGFP-Neo cells, the inhibition of
this pathway by PD98059 is superimposed by the PLC-
g1 signalling pathway.
Of interest was the finding of the diametrically
opposed effect of the PI3K inhibitor Ly294002 on
M13MDA435-1 and M13MDA435-3 hybrid cells. While
Ly294002 effectively inhibited the migratory activity of
M13MDA435-3 hybrid cells, the migration of
M13MDA435-1 hybrids was potently stimulated by this
compound. We assume that this effect might be attribu-
ted to a differential RAF-AKT crosstalk [37] in both
hybrid cell lines. The RAF-AKT crosstalk describes the
interplay between AKT and RAF-1 signalling, whereby a
strong PI3K/AKT activation leads to a AKT dependent
inhibition of RAF-1 concomitant with abrogation of
MAPK
p42/44 signalling [37]. Inhibition of AKT signalling,
e.g., by Ly294002 treatment, relieves this block and
restores RAF-1-MAPK
p42/44 signalling [37]. Moelling et
al. observed increased phosphorylated MAPK
p42/44 levels
in IGF and Ly294002 co-treated cells [37], which is
similar to our work.
The putative RAF-AKT crosstalk in M13MDA435-1
hybrid cells was further validated by Western Blot ana-
lysing RAF-1 phosphorylation at position S259, which is
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In fact, Western Blot analysis of LY294002 treated
M13MDA435-1 hybrid cells showed decreased pRAF-1
S259 levels, which were neither detected in
M13MDA435-3 hybrid cells nor in the parental cells.
This finding would be in view with the assumption of
an active RAF-AKT crosstalk in M13MDA435-1 hybrid
cells. Treatment of M13MDA435-1 cells with Ly294002
blocks PI3K/AKT signalling, thereby impairing AKT





Whether the differential activity of the RAF-AKT
crosstalk was attributed to the cell fusion process or to
another mechanism is unclear. Cell fusion is a random
process associated with chromosomal instability, loss of
single chromosomes and aneuploidy in emerging hybrid
cells [6,10,11]. As a consequence each hybrid clone ori-
ginate individually and because of that each hybrid
clone exhibit a unique gene expression profile concomi-
tant with a unique signal transduction cascade pattern.
On the other hand, Rommel and colleagues showed that
the regulation of RAF-AKT crosstalk also depended on
the differentiation state of the cell [48]. AKT activation
inhibited the RAF-MAPK pathways in differentiated
myotubes, but not in their myoblast precursors, which
might be attributed to a stage-specific ability of AKT to
form a complex with RAF [48]. Thus, the deactivated
RAF-AKT crosstalk in M13MDA435-3 hybrid cells
might be a relict of stem cell-like phenotype of
M13SV1-EGFP-Neo cells. In this cell line no RAF-AKT
crosstalk was observed. Activation of the RAF-AKT
crosstalk in M13MDA435-1 hybrid cells might thus be
attributed to some kind of a maturation/differentiation
process that may have occurred in this hybrid cell line
during its evolution.
The finding that both hybrid cells responded to EGF
with an increased migratory activity, whereas the paren-
tal tumour cell line MDA-MB-435-Hyg did not, indicate
the potency of cell fusion in changing the fate of cancer
cells. Moreover, cell fusion could not only revert the
migratory phenotype of a parental cancer cell, but also
could give rise to hybrid cells each exhibiting a unique
signal transduction cascade pattern. This knowledge
would of interest in case of anti-cancer therapies specifi-
cally targeting single molecules and pathways. As men-
tioned above, the HER2/HER3 heterodimer has been
referred to act as an oncogenic unit in breast cancer
[45,46] due to strong activation of the pro-survival
PI3K/AKT pathway. Because of that HER3 has been
recommended as a suitable target for novel anti-cancer
therapies. For instance, inhibition of HER2/HER3 het-
erodimer signalling either by shHER3 mediated knock-
down or pertuzumab/trastuzumab treatment was
correlated with markedly reduced growth of BT474M1
and MDA-MB-175 induced tumours in vivo [49]. Simi-
lar results were obtained by a Cre-mediated HER3 dele-
tion or by a chemically stabilized HER3 antisense
oligonucleotide, in a murine model of mammary carci-
noma [50]. While such strategies would effectively block
HER3/PI3K/AKT signalling it would be of interest to
investigate the effect of this blockage in the hybrid cells
used in this study. Inhibition of AKT signalling, e.g., by
Ly294002 treatment, can restore RAF-1-MAPK
p42/44 sig-
nalling [37]. Thus, a similar effect should occur in case
of HER3 inhibition, e.g., by using recombinant monoclo-
nal antibodies targeting HER2 and HER3 molecules.
In addition to EGF we also investigated the migratory
activity of the cells within the presence of SDF-1a since
the parental M13SV1-EGFP-Neo cell line and both
hybrid cell lines were slightly positive for CXCR4. The
SDF-1a receptor CXCR4 has been linked to the organ-
specific metastatic spreading of breast cancer [51,52].
The finding that both hybrid cells were positive for
CXCR4 may suggest that cell fusion might be a mechan-
ism how (breast) cancer cells could acquire the ability to
metastasise in an organ-specific manner. Several lines of
evidence indicated that fusion of tumour cells with
other cells, such as macrophages, gave rise to hybrid
cells exhibiting an increased metastatogenic capacity
[5,6,31,53]. However, cell migration data revealed that
the migratory activity of both hybrid cell lines (and the
parental breast cancer cell line) was markedly impaired
by this chemokine, which is contrary to parental
M13SV1-EGFP-Neo breast epithelial cells. Here CXCR4
expression was correlated to a slightly, but not signifi-
cantly increased migratory activity of the cells upon
SDF-1a stimulation.
The SDF-1a receptor CXCR4 belongs to the family of
G-protein coupled receptors (GPCRs) [54,55]. Recent
data indicated that CXCR4 signalling may not be limited
to Gai as first thought, but that CXCR4 can couple to
other Ga proteins such as Gaq,G ao and Gas [54,56].
Thus, the differential SDF-1a migratory activities of the
analysed cells might be attributed to differential expres-
sion levels of Ga subunits. For instance, adenyl cyclase
is activated by Gas, but blocked by Gai [54]. In neutro-
phil granulocytes the interleukin-8 (IL-8) dependent
activation of the adenyl cyclase/PKA pathway has been
associated with the induction of a stop-signal, thereby
impairing the cells overall and fMLP induced migration
in a dose-dependent manner [57]. Activation of the ade-
nyl cyclase/PKA pathway promotes the sequestration of
cytosolic calcium in cells [57], thereby impairing cell
migration.
Holland and colleagues demonstrated that association
of G-protein abg-heterotrimers with CXCR4 receptor
and induction of a SDF-1a specific signalling did only
Özel et al. Cell Communication and Signaling 2012, 10:10
http://www.biosignaling.com/content/10/1/10
Page 8 of 12occur in highly invasive breast cancer cell lines, but not
in non-invasive cell lines [58]. Here, the blockade of
non-metastatic cell lines seemed to be due to the inabil-
ity of G protein a and b subunits to form a heterotri-
meric complex with CXCR4, which, on the other hand,
was observable in highly invasive cell lines [58].
However, both hybrid cell lines as well as the parental
MDA-MB-435-Hyg breast cancer cell line responded to
SDF-1a treatment with a decreased migratory activity.
Thus we assume that these cells harbour a functional
CXCR4 receptor coupled with a functional G-protein
abg-heterotrimer. In addition to heterotrimeric G-pro-
tein dependent signals CXCR4, like all GPCRs, is a sub-
strate for G protein receptor kinases (GRKs) [56]. GRK-
mediated phosphorylation of CXCR4 creates a binding
site for b-arrestins, thereby enabling a heterotrimeric G-
protein independent signalling [56]. The CXCR4-b-
arrestin complex is a potent inducer of the MAPK
p42/44
pathway via RAF-1 [59]. MAPK
p42/44 phosphorylation
was observed in SDF-1a treated M13MDA435-1 hybrid
cells. However, both Gai and Gaq coupled GPCRs do
also stimulate MAPK activation [54] and thus it remains
unclear whether MAPK
p42/44 was activated in
M13MDA435-1 hybrid cells in a heterotrimeric G-pro-
tein dependent or independent manner.
Conclusions
In the present study we investigated the EGF- and SDF-
1a mediated migratory behaviour of the two hybrid cell
lines, derived from spontaneous fusion events [7,10], in
relation to their parental cells. In accordance to a pre-
vious study [7] each hybrid cell line exhibited a unique
migratory behaviour. Analysis of three major signal
transduction cascades (PLC-g1, PI3K/AKT, RAS-RAF-
MAPK) indicated that the hybrid cells’ unique migratory
behaviour is likely attributed to a unique signal trans-
duction cascade pattern in each hybrid cell line. Particu-
larly of interest was the finding of the diametrically
opposed L294002 effect on the migratory activity of
M13MDA435-1 and -3 hybrid cells. Our data indicate
that the Ly294002 mediated activation of the sponta-
n e o u sa sw e l la sE G Fa n dS D F - 1 a mediated migration
of M13MDA435-1 hybrid cells was most likely attribu-
ted to an active RAF-AKT crosstalk in these cells. We
thus conclude from our data that they nicely illustrate
the random/unpredictable nature of cell fusion. Even
though tumour hybrid cells may appear similar at a first
glance, they might differ in fundamental properties,
including differential kinetics of signal transduction cas-
cades and cross-talks. Our data provide evidence that
cell fusion between breast tumour cells and breast
epithelial cells exhibiting stem cell properties can give
rise to hybrid cells exhibiting a functional RAF-AKT
crosstalk. Inhibition of the AKT dependent RAF block
will restore RAF-1-MAPK
p42/44 signalling, which might
result in a progression of these cells in case of an anti-
AKT therapy. Thus, a thorough characterisation of
tumour tissue samples, including overall expression of
receptors and signal transduction molecules as well as




The M13SV1-EGF-Neo breast epithelial cell line, exhi-
biting stem-like characteristics, [60] was kindly provided
by James E. Trosko (Michigan State University, East
Lansing, MI) and was cultivated in MSU-1 basal media
(Sigma Aldrich, Taufkirchen, Germany) supplemented
with 10% foetal calf serum (FCS) (PAA Laboratories,
Linz, Austria), 1% Penicillin/Streptomycin (100 U/ml
Penicillin, 0.1 mg/ml Streptomycin; PAA Laboratories,
Linz, Austria), 10 μg/ml human recombinant EGF, 5 μg/
ml human recombinant Insulin, 0.5 μg/ml Hydrocorti-
sone, 4 μg/ml human Transferrin, 10 nM b-Oestrogen
(all chemicals were purchased from Sigma Aldrich,
Taufkirchen, Germany), and 400 μg/ml G418 (Biochrom
AG, Berlin, Germany) at 37°C and 5% CO2 in a humidi-
fied atmosphere. The breast cancer cell line MDA-MB-
435-Hyg was maintained in DMEM (PAA Laboratories,
Linz, Austria) supplemented with 10% FCS,1% Penicil-
lin/Streptomycin, and 200 μg/ml Hygromycin B (PAA
Laboratories, Linz, Austria). M13MDA435-1 and
M13MDA435-3 hybrid cells were cultivated in DMEM
(PAA Laboratories, Linz, Austria) supplemented with
10% FCS,1% Penicillin/Streptomycin, 400 μg/ml G418
(Biochrom AG, Berlin, Germany), and 200 μg/ml Hygro-
mycin B (PAA Laboratories, Linz, Austria) as described
previously [7].
Short tandem repeat analysis
STR analysis was performed as described previously [7].
In brief, genomic DNA of cells (1 × 10
6) was isolated
using the NucleoSpin
® Blood Kit (Macherey&Nagel,
Düren, Germany) in accordance to the manufacturer
instructions. Five polymorphic regions were amplified by
PCR. For primer pairs and PCR conditions pleased refer
to [7]. Separation of the PCR-fragments was performed
using a four-color laser induced fluorescence capillary
electrophoresis system (Prism 3130; ABI, Weiterstadt,
Germany) utilizing GeneScan Standard ROX-500 for
fragment length evaluation. Evaluation was done using
Genemapper v2.03 evaluation software (ABI, Weiter-
stadt, Germany).
Flow cytometry
Flow cytometry was performed on a FACScalibur flow
cytometer (Becton Dickenson, Heidelberg, Germany).
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5) were stained with the following antibo-
dies: anti-EGFR (clone 528; Merck KGaA, Darmstadt,
Germany), anti-c-erbB-2/HER2/neu (clone 9G6; Merck
KGaA, Darmstadt, Germany), anti-erbB-3/HER3 (clone
298; Santa Cruz Biotechnology, Heidelberg, Germany)
and PE-conjugated anti-CXCR4 (clone 44717; R&D Sys-
tems GmbH, Wiesbaden, Germany). Staining of intracel-
lular CXCR4 was performed as described previously
[36]. First, membrane bound CXCR4 was blocked with
non-conjugated anti-CXCR4 (clone 44717; R&D Systems
GmbH, Wiesbaden, Germany). Subsequently, cells were
fixed with 4% paraformaldehyde and permeabilized with
0.5% Triton X-100. Cells were washed thoroughly with
PBS and stained with PE-conjugated anti-CXCR4 (clone
44717; R&D Systems GmbH, Wiesbaden, Germany).
Isotype matched antibodies served as control: IgG1
(Beckman Coulter, Krefeld, Germany) and PE-conju-
gated IgG2b (R&D Systems GmbH, Wiesbaden). In case
of non-conjugated primary antibodies, cells were stained
with a secondary PE-conjugated goat-anti-mouse anti-
body (R&D Systems GmbH, Wiesbaden, Germany).
Data were analyzed using the WinMDI 2.8 software
(Scripps Reserach Institute, La Jolla, CA, USA).
Cell migration analysis
Cell migration analysis was performed by applying the
3D-collagen matrix migration assay combined with com-
puter-assisted cell-tracking as described previously
[7,36,42,61,62]. In brief, liquid collagen solution (Pure-
col; Nutacon BV, Leimuiden, The Netherlands) was
mixed with 10 × MEM (Sigma Aldrich, Taufkirchen,
Germany), 7.5% sodium bicarbonate solution (Sigma
Aldrich, Taufkirchen, Germany) and cells (6 × 10
4).
Depending on the experimental setting EGF (100 ng/ml;
Sigma Aldrich, Taufkirchen, Germany), SDF-1a (1 μg/
ml; PAN Biotech, Aidenkirchen, Germany), Ly294002
(500 nM; VWR International GmbH, Darmstadt, Ger-
many), and PD98059 (500 nM; VWR International
GmbH, Darmstadt, Germany) were added to the solu-
tion. The collagen-cell suspension was filled in self-con-
structed cell migration chambers and the collagen was
allowed to polymerize. Subsequently, cell migration
chambers were put under a microscope into wooden
boxes being tempered to 37°C. Cell migration within the
3D-collagen lattice was recorded for at least 15h by
time-lapse video microscopy. For data analysis, 30 cells
of each sample were randomly selected and two-dimen-
sional projections of the paths were digitized in 15 min
intervals.
Calcium measurements
Changes in the intracellular calcium levels of cells were
determined as described previously [36,47,61] in accor-
dance to the method described by Gergeley et al. [63].
Cells (5 × 10
5) were labelled with 4 μM Fluo-3 (Invitro-
gen). In dependence of the experimental setting, cells
were stimulated with either 100 ng/ml EGF (Sigma
Aldrich, Taufkirchen, Germany) or 0.1 μg/ml SDF-1a
(PAN Biotech, Aidenkirchen, Germany). Substances
were added after 50s. The tube was mixed, and acquisi-
tion was continued for a total of 204.80s. Measurements
were performed using a FACScalibur flow cytometer
(Becton Dickenson). For analysis, the mean fluorescence
intensity (MFI) of 10s intervals was determined. The
mean MFI of the first 50s of each calcium measurement
without a stimulus was defined as a baseline level (mean
MFIbaseline) and was compared to mean MFI of the first
60s after stimulation (mean MFIstimulation), which was
defined as the rate of calcium influx. The mean MFIsti-
mulation of each calcium measurement was calculated in
relation to the appropriate mean MFIbaseline of the same
experiment, which was set to 100%.
Western Blot
To investigate the AKT and MAPK
p42/44 phosphoryla-
tion levels in dependence of EGF and SDF stimulation
as well as in the presence of the PI3K inhibitor
Ly294002 and the MAPK
p42/44 inhibitor PD98059 1 ×
10
5 cells were treated with 100 ng/ml EGF (Sigma
Aldrich, Taufkirchen, Germany) or 1 μg/ml SDF-1a
PAN Biotech, Aidenkirchen, Germany) for 5 minutes or
were pretreated with 500 nM Ly294002 (VWR Interna-
tional GmbH, Darmstadt, Germany) or 500 nM
PD98059 (VWR International GmbH, Darmstadt, Ger-
many) for 30 minutes. Samples were separated by SDS-
PAGE on a 10% SDS polyacryamide gel and transferred
to PVDF nitrocellulose membranes (Millipore) under
semi-dry conditions. Membranes were blocked overnight
with 10% (w/v) non-fat dry milk in TBS-T. MAPK
p42/44,
pMAPK
p42/44, AKT, pAKT S473, RAF-1, pRAF-1 S259,
and elf4E were detected by using the following antibo-
dies: MAPK
p42/44 (rabbit polyclonal; Cell Signalling,
New England Biolabs, Frankfurt am Main, Germany),
pMAPK
p42/44 (rabbit polyclonal; Cell Signalling, New
England Biolabs, Frankfurt am Main, Germany), AKT
(clone 11E7; rabbit monoclonal, Cell Signalling, New
England Biolabs, Frankfurt am Main, Germany), pAKT
S473 (clone D9E; rabbit monoclonal, Cell Signalling;
New England Biolabs, Frankfurt am Main, Germany),
RAF-1 (rabbit polyclonal, Cell Signalling; New England
Biolabs, Frankfurt am Main, Germany), pRAF-1 S259
(rabbit polyclonal, Cell Signalling; New England Biolabs,
Frankfurt am Main, Germany), and elf4E (rabbit poly-
clonal; Cell Signalling, New England Biolabs, Frankfurt
am Main, Germany). For detection of primary antibodies
the HRP-conjugated secondary anti-rabbit IgG (Cell Sig-
nalling, New England Biolabs, Frankfurt am Main, Ger-
many) was used. Bands were visualised using the
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® Reagent (Cell Signalling, New England Bio-
labs, Frankfurt am Main, Germany) or the BM Chemilu-
minescence Western Blotting Substrate (POD) (Roche
Diagnostics Geutschland GmbH, Mannheim, Germany)
in accordance to the manufacturers’ instructions. Blots
were detected with the Aequoria Macroscopic Imaging
system (Hamamatsu Photonics Germany, Herrsching am
Ammersee, Germany) or by conventional exposure to
Kodak T-MAT Plus DG X-ray films (Röntgenversand
Wurzbacher, Obernissa, Germany).
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